Hospital Universitario De Fuenlabrada
- Address
- lock Available on a paid plan
Digestive and Inflammatory Bowel Disease Research
At Hospital Universitario De Fuenlabrada, clinical trials in the Digestive System Diseases area focus strongly on Crohn’s disease, ulcerative colitis, and eosinophilic esophagitis. This research is aimed at testing new treatment options, improving long-term disease control, and evaluating how well therapies reduce symptoms and inflammation.
- Moderately to severely active Crohn’s disease and treatment response
- Ulcerative colitis control, remission, and maintenance of benefit
- Eosinophilic esophagitis and improvement of esophageal inflammation
- New approaches for patients who have not responded well to conventional care
The site’s gastroenterology team is contributing to studies that aim to make treatment more effective and more durable for people living with chronic intestinal disease.
Breast Cancer and Oncology Trials
A large share of the research portfolio is centered on Neoplasms, especially breast cancer in its early-stage, metastatic, HER2-positive, HER2-negative, and triple-negative forms. These trials are designed to compare cancer therapies, improve disease-free survival, and refine treatment strategies for patients at different stages of disease.
- Early breast cancer and prevention of recurrence
- Metastatic breast cancer and longer disease control
- HER2-positive, HER2-negative, and hormone receptor-positive disease
- Triple negative breast cancer and post-surgical treatment decisions
This oncology research includes testing newer targeted and combined treatment approaches to help identify options that may improve outcomes while maintaining tolerability.
Colorectal Cancer and Peritoneal Disease Studies
The research program also includes trials in Digestive System Diseases and Neoplasms focused on colorectal cancer, including locally advanced disease, metastatic disease, and peritoneal metastases. The goal is to evaluate better treatment combinations and surgical strategies that may lower recurrence and extend survival.
- Locally advanced colon cancer and treatment intensification or de-escalation
- Metastatic colorectal cancer and sequencing of systemic therapies
- Peritoneal metastases and recurrence prevention after surgery
- Studies assessing whether adding targeted regional treatment improves outcomes
These studies reflect a strong interest in improving care for complex gastrointestinal cancers through both medical and surgical research.
Immune-Mediated and Autoimmune Disease Research
Trials in Immune System Diseases and Immune System Phenomena at this site address conditions such as rheumatoid arthritis, hidradenitis suppurativa, and alopecia areata. The main purpose is to assess new therapies that may better control inflammation, reduce flare-ups, and improve quality of life.
- Rheumatoid arthritis and control of joint inflammation
- Hidradenitis suppurativa and reduction of skin lesions
- Alopecia areata and restoration of hair growth
- Evaluation of targeted anti-inflammatory treatments
This area highlights ongoing work to find more precise and better-tolerated options for chronic immune-related diseases.
Skin and Allergy Research
The site is active in Skin and Connective Tissue Diseases and allergy-related research, including atopic dermatitis, allergic rhinitis, and pollen-related respiratory allergy. These studies are focused on improving symptom relief, reducing itching and irritation, and testing whether immunotherapy or biologic treatments can provide stronger control.
- Atopic dermatitis in children and adults
- Allergic rhinitis and rhinoconjunctivitis linked to grass and olive pollen
- Allergen immunotherapy to reduce sensitivity and symptoms
- Studies of treatments that aim to improve daily comfort and quality of life
This research combines allergy and dermatology expertise to support better management of common but persistent inflammatory conditions.
Blood, Metabolic, and Cardiovascular Research
Trials in Hemic and Lymphatic Diseases, Nutritional and Metabolic Diseases, and Cardiovascular Diseases include multiple myeloma, chemotherapy-related low platelet counts, and studies in obesity-related cardiovascular risk. The purpose of this work is to improve treatment delivery, support safer cancer care, and evaluate strategies that may reduce cardiovascular events.
- Newly diagnosed multiple myeloma and deeper treatment response
- Chemotherapy-induced thrombocytopenia and maintaining planned cancer treatment
- Cardiovascular disease and prevention of major adverse events
- Research aimed at supporting treatment safety across several specialties
At this Hospital/Clinic/Other health care facility, these studies show a broad interest in both disease control and the practical safety of ongoing therapy.
Respiratory, Critical Care, and Infection-Related Studies
The portfolio also reaches into Respiratory Tract Diseases and Virus Diseases, with studies involving severe respiratory illness, acute respiratory distress syndrome, and advanced lung cancer. These trials are designed to test supportive care approaches, new cancer treatments, and therapies for infection-related complications.
- Acute respiratory distress syndrome linked to viral infections
- Advanced non-small cell lung cancer and treatment effectiveness
- Critical care research on sedation and ventilation support
- Evaluation of therapies intended to improve survival or recovery
This reflects a multidisciplinary research environment that extends beyond gastroenterology into broader hospital-based clinical investigation.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 13 therapeutic areas and 15 of 93 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 88 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 18 by active trials.
- 1AbbVie Deutschland GmbH & Co. KG2active
lock +17 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG5trials
lock +9 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital Universitario De Fuenlabrada
lock Showing 1 of 48 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Double-Blind, Randomized Withdrawal Study of Subcutaneous Secukinumab for Long-Term Efficacy and Safety in Moderate to Severe Hidradenitis Suppurativa | Novartis Pharma AG | Phase III | Not Recruiting | Mar 2020 | Jun 2026 |
IMP list
lock Showing 1 of 93 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Anastrozole | 5 | Unknown | 2019-05-22 | 2025-12-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
